Abbreviations used: BDNF, brain-derived neurotrophic fac tor; NGF, nerve growth factor; sse, standard saline citrate.
Summary:
The neuroprotective action of brain-derived neurotrophic factor (BDNF) was evaluated in a rat model of transient forebrain ischemia. A continuous intraven tricular infusion of BDNF for 7 days starting immediately before the onset of ischemia significantly increased the number of pyramidal cells in the vulnerable CA 1 sector of Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin gene family (Leibrock et aI., 1989 ) that acts as a potent survival factor for some neuronal populations in culture (Johnson et aI. , 1986; Alderson et aI., 1990; Hyman et aI., 199 1; Kniisel et aI., 199 1) . In vivo, BDNF has been shown to increase the number of sensory neurons in the dorsal root and nodose ganglion of developing quails (Hofer and Barde, 1988) and to support the survival of motoneurons in the facial nerve after axotomy (Sendtner et aI., 1992) . Transient ischemia (Lindvall et aI., 1992) and glutamate receptor acti vation (Zafra et aI., 199 1) have recently been shown to elevate mRNA for nerve growth factor (NGF) and BDNF in the rat hippocampus, but the potential role of BDNF in reducing neuronal death after se lective brain lesions remains to be defined. Here we show that BDNF, in contrast to NGF, significantly prevents cell death in the CAl sector of the hippo campus after transient forebrain ischemia. This finding, together with the widespread occurrence of the hippocampus. In situ hybridization experiments sug gest the neuroprotection to be mediated via trkB -recep tors in the hippocampus. The data indicate a therapeutic potential for the treatment of cerebral ischemia. Key Words: Brain-derived neurotrophic factor-Hippocam pus-Ischemia-Protection-Rat. trkB receptors in the brain, suggests a therapeutic potential for BDNF in cerebral ischemia.
MATERIALS AND METHODS
Male Wi star rats received continuous intraventricular infusions of BDNF starting immediately before the induc tion of ischemia and ending 7 days later. Rats (320-350 g) were fasted overnight, anesthetized with 1-2% halothane in a 70:30 mixture of nitrous oxide/oxygen, and placed in a David Kopf stereotaxic apparatus. A cannula device connected to a subcutaneously implanted miniosmotic pump (Alzet model 2001, Palo Alto, CA, U.S.A.) was inserted in the lateral ventricle at -0.4 mm to the bregma, 1.4 mm lateral to the midline, and 3.5 mm below the dura and fixed with dental cement and stainless-steel screws to the skull. Recombinant BDNF was delivered intraventricularly at a rate of 0.013 ILg/h dissolved in ster ile artificial cerebrospinal fluid containing 0.1% autolo gous rat serum as the carrier protein. Controls received similar infusions of the vehicle alone. Infusion was started 60-90 min before the induction of ischemia. Reg ular delivery of the pumps was checked at the end of infusion.
Transient forebrain ischemia was induced in artificially ventilated rats (1-1.5% halothane in a 30:70 (vol/vol) mix ture of N20 and 02) according to Smith et al. (1984) . A silicon catheter for withdrawal of blood was inserted in the jugular vein and advanced into the inferior caval vein. After discontinuation of halothane, muscle paralysis was maintained with suxamethonium chloride (courtesy of Dr. B. Kutscher, Asta Pharma, Frankfurt, Germany) and blood clotting prevented by heparin (200 IU/kg). Needle electrodes were placed in the temporalis muscle for EEG recording. After stabilization of physiological parameters for 30 min, 5 mg/kg trimetaphan (Hoffmann-LaRoche, Grenzach-Wyhlen, Germany) was injected, the carotid arteries were clamped, and the blood pressure was low ered to 40 mm Hg by withdrawal of blood. The onset of an isoelectric EEG was taken as the indicator of ischemia. Blood pressure was recorded with a pressure transducer connected to the tail artery cannula. After 10 min, the carotid clamps were released and the shed blood was re infused. Rats received I mmollkg sodium bicarbonate to counteract systemic acidosis. Physiological variables were controlled routinely. The temperature was closely held at 37°C throughout the experiment and up to 2 h afterward. The freely moving rats were reanesthetized at day 7 and perfusion-fixed. Staining was performed for perikarya (Nissl) and with celestine blue/acid fuchsin. Necrotic pyramidal cells were counted within the entire CA 1, CA3, and CA4 subfields using a measuring grid. The investigator performing the animal surgery and the cell counting was blinded to the treatment. Animal care and surgery conformed to the Federal Regulations of the Animal Protection Act for biomedical research (permit of the government of lower Frankonia, Germany, file 211-2531.01-9/9/88). As described previously (Castren et aI., 1992) , in situ hybridization was performed on frozen 12-J..l m sections, which were postfixed in 4% buffered paraformaldehyde, treated with acetic anhydride, and hy bridized overnight at 37°C in a buffer containing 50% formamide, 4x standard saline citrate (SSC), 50 mM phosphate buffer, pH 7.0, 1% laurylsarcosine, 1 x Den hardt's solution, 0.5 mg/ml denatured salmon sperm DNA, 10% dextran sulfate, and 100 mM dithiothreitol. The probe was an oligonucleotide directed against the intracellular juxtamembrane region (nucleotides 1409-1448) of the rat trkB sequence (Klein et aI., 1990) , thus recognizing the functional trkB receptor with the tyrosine kinase domain, whereas other variants of trkB lack this intracellular region (Middlemas et aI., 1991) . The probe was end-labeled with terminal transferase and 35S-dATP. This oligonucleotide does not recognize the truncated forms of trkB. The sections were washed under increas ing stringency up to 0.5 x SSC at 52°C, dehydrated, and exposed to Hyperfilm I)-Max (Amersham, UK) for 14 days. Antisense oligonucleotide against the complemen tary sequence showed only background hybridization (re sults not shown). 
RESULTS
Physiological variables (Table 1) were in the range recorded previously (Beck and Bielenberg, 1990) . When the animals were sacrificed 7 days af ter the insult, a considerable loss of pyramidal neu rons occurred in the CA 1 region of the hippocam pus, as shown in Fig. 1 . Histological evaluation re vealed that CA 1 neurons of ischemic brains were reduced to 20% of control values (Table 2) . After BDNF treatment, the percentage of surviving neu rons surged significantly, to 62% of control values. No cell loss was observed in the CA3 area. Minor damage was recorded in the CA4 sector. Here, the percentage of surviving neurons rose significantly, from 39% in untreated rats to 47% after BDNF in fusion.
In situ hybridization revealed a consistently high signal for the functional trkB receptor in hippocam pal neurons, including the CAl sector (Fig. 2) .
DISCUSSION
The present data clearly indicate that BDNF pre vents neuronal death due to transient ischemia. Nu merous attempts have been made to evaluate the neuroprotective potential of growth factors for the treatment of ischemic cell damage. Basic fibroblast growth factor promoted angiogenesis in a model of carotid ligation in rats but failed to rescue CAl py ramidal cells in the four-vessel occlusion model (Hara et aI., 1991; Lyons et aI., 1991) . The results obtained with NGF have been equivocal. In our hands, NGF failed to protect hippocampal neurons in an experimental paradigm identical to the present one (Beck et aI., 1992) . In contrast to this finding, Buchan et aI. (1990) , using a fivefold higher dose than ours in the four-vessel occlusion model and chronically pretreating the rats for 11 days before the insult, and Shigeno et al. (1991) , injecting gerbils with a bolus roughly six times the total dose we used, did see significant improvements in neurolog ical outcome. A recent publication has underscored the importance of using a sufficiently high NGF dosage for a pharmacological effect (Yamamoto et aI., 1992) . Regardless of the dosage, however, any protective effect of NGF on hippocampal cells re mains enigmatic, since neither immunohistochem istry nor in situ hybridization has provided evidence of the presence on hippocampal neurons of the p75 low-affinity NGF receptor or the p140tr k mRNA, representing the high-affinity binding site. In con trast, as shown in Fig. 2 , trkB mRNA, encoding for the BDNF tyrosine kinase receptor (Klein et aI., 1990) , is highly expressed in hippocampal neurons, including the CAl sector. The presence of func tional trkB receptors in the hippocampus provides a rational basis for the pharmacological effect of BDNF observed in the present study. Moreover, the expression of trkB mRNA is apparently en hanced by increased activity in the excitatory per forant pathway to the hippocampus (Falkenberg et aI., 1992) . This suggests the interesting possibility that under pathophysiological conditions, such as after an ischemic insult, trkB might be upregulated, favoring an increased cellular response to injected BDNF.
The exact cellular mechanism for the neuropro tective activity of BDNF is not known, but recent in vitro data illustrate a protective effect of BDNF on glutamate-induced cell death in cerebellar cultures (Lindholm et aI., 1993) . Excessive release of gluta mate and activation of glutamate receptors are thought to contribute to the neurotoxicity charac teristic of some acute and chronic neurological dis-eases (Rothman and Olney, 1986; Choi, 1988) , and the reduction of ischemic cell death by BDNF may thus be explained along these lines.
The reduction of ischemic damage in the hippo campus afforded by BDNF implies a potential ther apeutic role for this neurotrophic factor in such con ditions. The results encourage further studies on different modes of BDNF administration as well as on the effective time window for the action of BDNF in ischemia.
